Egyptian Journal of Medical Human Genetics (Sep 2022)

Biomarker potential of the GRP78 cell-free RNA in endometrial cancer

  • Busra Aynekin,
  • Hilal Akalin,
  • I. Ipek Muderris,
  • Gokhan Acmaz,
  • Hulya Akgun,
  • Izem Olcay Şahin,
  • Nuriye Coşkun Gokce,
  • Zahraa Alzaidi,
  • Gözde Erturk Zararsiz,
  • Yusuf Ozkul,
  • Munis Dundar,
  • Çetin Saatci

DOI
https://doi.org/10.1186/s43042-022-00355-0
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Circulating tumor cells represent an opportunity for the assessment of early recurrent disease or for real-time tracing of cancer. Glucose Regulated Protein 78 (GRP78) is known in the literature as a stress factor in endometrial cancer. We aimed to investigate the importance of the gene by targeting tumor traces circulating in the cell fluids of patients with Type 1 endometrial cancer, examining cell-free RNAs in patients’ samples and performing ROC analysis. Methodology In this study, 32 endometrial cancer patients and 20 controls were included. This in vitro study evaluated, the GRP78 cell-free mRNA expression levels in endometrial cancer patients, by quantitative real-time polymerase chain reaction qRT–PCR Light Cycler. Receiver operating characteristic (ROC) analysis is a tool used to identify the precision of a diagnostic test or prediction model. In our study, we investigated whether the expression levels of cell-free GRP78 mRNA could be used as a diagnostic criterion. Results The ROC curve results for endometrial cancer diagnostic criterion of cfRNA GRP78 mRNA indicated quite a significant value (p < 0.001). Conclusion Current findings show that cell-free mRNA GRP78 is now a criterion that can be used together with smear mRNA GRP78 without the need for invasive methods in endometrial cancer studies.

Keywords